公开(公告)号：US20240294579A1

公开(公告)日：2024-09-05

申请号：US18616134

申请日：2024-03-25

申请人： CureVac SE

发明人： Thomas KRAMPS ,  Margit SCHNEE ,  Daniel VOSS ,  Benjamin PETSCH

IPC分类号： C07K14/005 ,  A61K39/00 ,  A61K39/12 ,  A61K39/155 ,  A61K48/00 ,  C07K16/10 ,  C12N7/00

CPC分类号： C07K14/005 ,  A61K39/12 ,  A61K39/155 ,  C07K16/1027 ,  C12N7/00 ,  A61K2039/505 ,  A61K2039/53 ,  A61K2039/6031 ,  A61K48/00 ,  C07K2317/24 ,  C12N2760/18534

摘要： The present invention relates to an mRNA sequence, comprising a coding region, encoding at least one antigenic peptide or protein of RSV infections Respiratory syncytial virus (RSV) or a fragment, variant or derivative thereof. Additionally the present invention relates to a composition comprising a plurality of mRNA sequences comprising a coding region, encoding at least one antigenic peptide or protein of RSV infections Respiratory syncytial virus (RSV) or a fragment, variant or derivative thereof. Furthermore it also discloses the use of the mRNA sequence or the composition comprising a plurality of mRNA sequences for the preparation of a pharmaceutical composition, especially a vaccine, e.g. for use in the prophylaxis or treatment of RSV infections Respiratory syncytial virus (RSV) infections. The present invention further describes a method of treatment or prophylaxis of RSV infections using the mRNA sequence.

公开(公告)号：US20240247052A1

公开(公告)日：2024-07-25

申请号：US18630437

申请日：2024-04-09

申请人： Merck Sharp & Dohme LLC

发明人： Kalpit A. Vora ,  Kara S. Cox ,  Aimin Tang ,  Zhifeng Chen ,  Daniel DiStefano ,  Lan Zhang ,  Hua-Poo Su

IPC分类号： C07K16/10 ,  A61K39/00 ,  A61K39/42 ,  A61P31/14

CPC分类号： C07K16/1027 ,  A61K39/42 ,  A61P31/14 ,  A61K2039/505 ,  A61K2039/54 ,  A61K2039/545 ,  C07K2317/14 ,  C07K2317/21 ,  C07K2317/34 ,  C07K2317/41 ,  C07K2317/524 ,  C07K2317/565 ,  C07K2317/732 ,  C07K2317/76 ,  C07K2317/92 ,  C07K2317/94

摘要： The present invention relates to monoclonal antibodies which have high anti-RSV neutralizing titers. The invention further provides for isolated nucleic acids encoding the antibodies of the invention and host cells transformed therewith. The invention yet further provides for diagnostic, prophylactic and therapeutic methods employing the antibodies and nucleic acids of the invention, particularly as a passive immunotherapy agent in infants and the elderly.

公开(公告)号：US12006354B2

公开(公告)日：2024-06-11

申请号：US16616318

申请日：2018-05-22

申请人： NOVARTIS AG

发明人： Jonathan Deane ,  Yaiza Diaz-De-Durana ,  Michael DiDonato ,  Christophe Filippi ,  Glen Spraggon

IPC分类号： C07K14/55 ,  A61K38/20 ,  A61K39/395 ,  A61K47/68 ,  A61P35/00 ,  C07K16/08 ,  C07K16/10 ,  C07K19/00 ,  C12N5/071 ,  C12N5/0783 ,  A61K39/00 ,  A61K45/06

CPC分类号： C07K16/1027 ,  A61K38/2013 ,  A61K39/3955 ,  A61K47/6801 ,  A61P35/00 ,  C07K14/55 ,  C07K19/00 ,  C12N5/0636 ,  C12N5/0682 ,  A61K2039/505 ,  A61K45/06 ,  C07K2317/56 ,  C07K2317/565 ,  C07K2317/94 ,  C07K2319/30

摘要： The present disclosure provides for IL2 engrafted into the CDR sequences of an antibody having preferred therapeutic profiles over molecules known and used in the clinic. In particular, the provided antibody cytokine engrafted protein compositions increase or maintain CD8+ T effector cells while reducing the activity of Treg cells. Additionally, provided compositions convey improved half-life, stability and producibility over recombinant human IL2 formulations such as Proleukin®.

公开(公告)号：US11981726B2

公开(公告)日：2024-05-14

申请号：US18065172

申请日：2022-12-13

申请人： Merck Sharp & Dohme LLC

发明人： Kalpit A. Vora ,  Kara S. Cox ,  Aimin Tang ,  Zhifeng Chen ,  Daniel DiStefano ,  Lan Zhang ,  Hua-Poo Su

IPC分类号： C07K16/10 ,  A61K39/00 ,  A61K39/42 ,  A61P31/14 ,  C07K14/005 ,  C07K16/00 ,  C07K16/28

CPC分类号： C07K16/1027 ,  A61K39/42 ,  A61P31/14 ,  A61K2039/505 ,  A61K2039/54 ,  A61K2039/545 ,  C07K2317/14 ,  C07K2317/21 ,  C07K2317/34 ,  C07K2317/41 ,  C07K2317/524 ,  C07K2317/565 ,  C07K2317/732 ,  C07K2317/76 ,  C07K2317/92 ,  C07K2317/94

摘要： The present invention relates to monoclonal antibodies which have high anti-RSV neutralizing titers. The invention further provides for isolated nucleic acids encoding the antibodies of the invention and host cells transformed therewith. The invention yet further provides for diagnostic, prophylactic and therapeutic methods employing the antibodies and nucleic acids of the invention, particularly as a passive immunotherapy agent in infants and the elderly.

公开(公告)号：US20240043509A1

公开(公告)日：2024-02-08

申请号：US18448089

申请日：2023-08-10

申请人： B & H Biotechnologies, LLC

发明人： Huiru WANG

IPC分类号： C07K16/10 ,  A61K39/42 ,  C07K16/00 ,  A61K35/16 ,  A61K39/12 ,  A61K39/145 ,  A61K39/15 ,  A61K39/235 ,  A61K39/29 ,  A61K47/26 ,  C07K16/08

CPC分类号： C07K16/1018 ,  A61K39/42 ,  C07K16/1027 ,  C07K16/00 ,  A61K35/16 ,  A61K39/12 ,  A61K39/145 ,  A61K39/15 ,  A61K39/235 ,  A61K39/29 ,  A61K39/292 ,  A61K47/26 ,  C07K16/081 ,  C07K16/082 ,  C07K16/10 ,  C07K16/109 ,  A61K2039/545

摘要： The present invention discloses products and the methods of uses of the products for preventing and treating infectious diseases and the disorders or conditions inducible by harmful antibodies. The harmful antibodies are induced during infection, or vaccination, or use of therapeutic antibodies. The products of the present disclosure comprise immunoglobulin products, scrum or plasma, specific antibodies to viral pathogens.

公开(公告)号：US20230399383A1

公开(公告)日：2023-12-14

申请号：US18309475

申请日：2023-04-28

申请人： MEDIMMUNE LIMITED

发明人： Brian LOBO ,  Deborah GOLDBERG

IPC分类号： C07K16/10 ,  A61K39/395

CPC分类号： C07K16/10 ,  A61K39/39591 ,  C07K16/1027 ,  C07K2317/21 ,  C07K2317/94 ,  C07K2317/522 ,  C07K2317/92

摘要： The present invention provides a formulation comprising: (i) an anti-RSV monoclonal antibody; and (ii) an ionic excipient; wherein the monoclonal antibody is present at a concentration of about 50 mg/ml or greater and the ionic excipient is present at a concentration of between 50 and 150 mM and the formulation has a pH of about 5.5 to about 7.5.

公开(公告)号：US11827694B2

公开(公告)日：2023-11-28

申请号：US18173006

申请日：2023-02-22

申请人： GLAXOSMITHKLINE BIOLOGICALS SA

发明人： Kurt Swanson ,  Philip R. Dormitzer

IPC分类号： C07K16/10 ,  A61K39/155 ,  A61K39/12 ,  C07K14/005 ,  A61K39/00

CPC分类号： C07K16/1027 ,  A61K39/12 ,  A61K39/155 ,  C07K14/005 ,  A61K39/00 ,  A61K2039/5252 ,  A61K2039/5256 ,  A61K2039/5258 ,  A61K2039/53 ,  A61K2039/55505 ,  A61K2039/55555 ,  A61K2039/55561 ,  A61K2039/55566 ,  A61K2039/55572 ,  C07K2317/76 ,  C07K2319/00 ,  C07K2319/21 ,  C07K2319/50 ,  C07K2319/73 ,  C12N2760/18522 ,  C12N2760/18534 ,  C12N2770/36143

摘要： The present invention relates to immunogenic compositions comprising RSV F protein, methods for preparing compositions that contain RSV F protein ecto-domain polypeptides, and to certain engineered RSV F proteins and nucleic acids that encode the engineered RSV F proteins. Compositions prepared using the methods can contain RSV F protein ecto-domain polypeptides in a predominant or single desired form and conformation. The invention also relates to methods for inducing an immune response to RSV F.

公开(公告)号：US20230365695A1

公开(公告)日：2023-11-16

申请号：US18305292

申请日：2023-04-21

申请人： THE SCRIPPS RESEARCH INSTITUTE

发明人： Feng WANG ,  Yong ZHANG ,  Yan LIU ,  Peter G. SCHULTZ

IPC分类号： C07K16/28 ,  C07K14/505 ,  C07K14/535 ,  C07K14/575 ,  C07K14/435 ,  C07K14/61 ,  A61K39/395 ,  C07K16/10 ,  C07K14/705 ,  A61K47/65 ,  A61K47/68 ,  C07K16/32 ,  C07K14/47 ,  C07K14/605 ,  C07K14/64 ,  C07K14/81

CPC分类号： C07K16/2863 ,  C07K14/505 ,  C07K14/535 ,  C07K14/5759 ,  C07K14/43522 ,  C07K14/61 ,  A61K39/395 ,  C07K14/57563 ,  C07K16/2866 ,  C07K16/1027 ,  C07K14/70503 ,  A61K47/65 ,  A61K47/6889 ,  C07K16/32 ,  C07K14/47 ,  C07K14/605 ,  C07K14/64 ,  C07K14/811 ,  C07K2317/565 ,  C07K2317/92 ,  C07K2319/00 ,  C07K2318/10 ,  C07K2319/73 ,  C07K2319/50 ,  A61K2039/505

摘要： Disclosed herein are immunoglobulin fusion proteins comprising a first antibody region, a first therapeutic agent, and a first connecting peptide; wherein the first therapeutic agent is attached to the first antibody region by the connecting peptide; and wherein the connecting peptide does not comprise a region having beta strand secondary structure. The connecting peptide may comprise an extender peptide. The extender peptide may have an alpha helical secondary structure. The connecting peptide may comprise a linker peptide. The linker peptide may not comprise any secondary structure. Also disclosed herein are compositions comprising the immunoglobulin fusion proteins and methods for using the immunoglobulin fusion proteins for the treatment or prevention of a disease or condition in a subject.

公开(公告)号：US20230365660A1

公开(公告)日：2023-11-16

申请号：US18302400

申请日：2023-04-18

申请人： MEDIMMUNE LIMITED

发明人： Nancy ULBRANDT ,  Nicole KALLEWAARD-LELAY ,  Andy Q. YUAN ,  Bettina RICHTER

IPC分类号： C07K16/10

CPC分类号： C07K16/1027 ,  A61K2039/505

摘要： This application provides antibodies and functional equivalents thereof which are capable of specifically binding RSV, as well as means and methods for producing them.

公开(公告)号：US20230357371A1

公开(公告)日：2023-11-09

申请号：US18323192

申请日：2023-05-24

申请人： GLAXOSMITHKLINE BIOLOGICALS SA

发明人： Kurt SWANSON ,  Philip R. DORMITZER

IPC分类号： C07K16/10 ,  A61K39/155 ,  A61K39/12 ,  C07K14/005

CPC分类号： C07K16/1027 ,  A61K39/155 ,  A61K39/12 ,  C07K14/005 ,  A61K2039/5252

摘要： The present invention relates to immunogenic compositions comprising RSV F protein, methods for preparing compositions that contain RSV F protein ecto-domain polypeptides, and to certain engineered RSV F proteins and nucleic acids that encode the engineered RSV F proteins. Compositions prepared using the methods can contain RSV F protein ecto-domain polypeptides in a predominant or single desired form and conformation. The invention also relates to methods for inducing an immune response to RSV F.